Abstract:BACKGROUNDReplication-repair deficiency (RRD) stemming from mismatch repair and polymerase proofreading gene defects (MMRD/PPD) lead to hypermutant childhood cancers, most frequently brain tumors. While medulloblastoma is reported, the clinical, genomic and immune landscape remains unknown. METHODSWe analysed the genome, methylome, transcriptome (bulk, single-nuclei) and immune-microenvironment of the largest cohort of RRD-medulloblastoma patients enrolled by the International RRD Consortium and correlated these to clinical outcomes. RRD mice-models were used to preclinically assess response to immunotherapy. Results: RESULTSRRD-medulloblastoma (n=43) were enriched for anaplasia (61%) and localised disease (77%). Methylation/nano-string-based subgrouping failed to classify 40%, while the remaining clustered with the SHH-subgroup. Copy-number changes were notably infrequent (<20%). All tumors harboured hypermutation and microsatellite instability in contrast to non-RRD controls (p<0.0001). Pathogenic variants were frequent in POLE/POLD1 (80%), TP53 (48%) and SHH-pathway genes ( PTCH1, SUFU, SMO : 56%). Interestingly, some tumors additionally had glioma-driver alterations ( ATRX, NF1 : ~50%), similar to RRD cerebellar glioblastoma, but distinct from both non-RRD medulloblastoma (n=791) and hemispheric glioblastoma (n=733) controls. Moreover, although bulk-transcriptome matched non-RRD SHH medulloblastoma, single-nuclei analyses suggested an earlier cell-of-origin potentially explaining the heterogenous phenotypes resulting from the driver mutations. Uniquely, immune analyses (gene expression and immunohistochemistry) demonstrated high intra-tumoral CD8 T-cell infiltration. Three-year progression-free survival was 60%. Outcome was worse for RRD-medulloblastoma harbouring TP53 -mutation (p=0.04) and failing subgroup-classification (p=0.004). Nestin/Cre MSH2 -/- POLE;p.S459F mice developing medulloblastoma recapitulated human disease and demonstrated response to anti-PD1 monotherapy. Recurrent/progressive human tumors including those harbouring TP53 -mutations exhibited radiological responses to anti-PD1 monotherapy, which was associated with prolonged ongoing survival in comparison to those not treated with checkpoint-inhibitors (p=0.02). CONCLUSIONSHypermutant RRD-medulloblastoma reveal heterogenous phenotypes due to unique spectrum of driver mutations and an early cell of origin. Their immune-hot microenvironment allows successful salvage treatment with checkpoint-inhibitors for those failing chemo-radiation, including the high-risk SHH/TP53-mutant and unclassified subgroups.

Null Mutation Of Dna Strand Break-Binding Molecule Poly(Adp-Ribose) Polymerase Causes Medulloblastomas In P53(-/-) Mice

Author Correction: Failure of Human Rhombic Lip Differentiation Underlies Medulloblastoma Formation

Childhood cancer mutagenesis caused by transposase-derived PGBD5

Ten-eleven translocation protein 1 modulates medulloblastoma progression

Ezh2 Delays Activation of Differentiation Genes During Normal Cerebellar Granule Neuron Development and in Medulloblastoma

Modeling the Etiology of p53-mutated Cancer Cells

Loss of nuclear envelope phosphatase CTDNEP1 drives aggressive medulloblastoma by triggering MYC amplification and genomic instability

DNA Strand Break-Sensing Molecule Poly(ADP-Ribose) Polymerase Cooperates with P53 in Telomere Function, Chromosome Stability, and Tumor Suppression

Establishment and Characterization of a Mouse Medulloblastoma Cell Line

Medulloblastomas Overexpress the P53-Inactivating Oncogene WIP1/PPM1D

Loss of phosphatase CTDNEP1 potentiates aggressive medulloblastoma by triggering MYC amplification and genomic instability

The p53 tumor suppressor protein protects against chemotherapeutic stress and apoptosis in human medulloblastoma cells

N-myc Alters the Fate of Preneoplastic Cells in a Mouse Model of Medulloblastoma.

The Study of Molecular Pathogenesis in Medulloblastoma:Single-Strand Conformation Polymorphism Analysis of PTEN Tumor Suppressor Gene

PTCH1 -mutant human cerebellar organoids exhibit altered neural development and recapitulate early medulloblastoma tumorigenesis

Immu-14. Trans-Species Analysis Of Replication-Repair Deficient (Rrd) Medulloblastoma And Response To Immune Checkpoint Inhibition: An Irrdc Report

Simultaneous Nbs1 and P53 Inactivation in Neural Progenitors Triggers High-Grade Gliomas.

Genetic Alterations of DLC1 in Medulloblastoma and Primitive Neuroectodermal Tumor

Failure of human rhombic lip differentiation underlies medulloblastoma formation

MBRS-54. POOR SURVIVAL IN REPLICATION REPAIR DEFICIENT HYPERMUTANT MEDULLOBLASTOMA AND CNS EMBRYONAL TUMORS: A REPORT FROM THE INTERNATIONAL RRD CONSORTIUM

Augmented cancer resistance and DNA damage response phenotypes in PPM1D null mice.